Skip to Content
COVID-19 Resources
Cancer Imaging Program (CIP)
Contact CIP
Show menu
Search this site
Last Updated: 10/28/16

Newsletter No. 119 — September 2009

Funding Announcements
Image-guided Drug Delivery in Cancer (R01)(NCI) (PA-09-253)
Application Receipt Date(s): Multiple dates, see announcement.
This NCI FOA encourages innovative translational research in the development of quantitative in vivo imaging characterization of image-guided drug delivery (IGDD) in cancer, including characterizations of the target, delivery validation, and therapy response. This FOA will support research in development of integrated imaging-based platforms for multifunctional and multiplexed drug delivery systems in cancer. Validation studies in non-human primates or large animal models and first-in-human studies directed towards translation of IGDD technology into the clinic will be considered appropriate for this FOA.

Optimization of Small Molecule Probes for the Nervous System (Multiple institutes) (R21: PAR-09-251; R41: PAR-09-259; R43: PAR-09-260)
Application Receipt Date(s): Multiple dates, see appropriate announcement.
This FOA issued by participating institutes of the National Institutes of Health, encourages research grant applications that propose to develop new small molecule probes for investigating biological function in the nervous system via the application of advanced medicinal chemistry and the biological testing of compounds. Eligible investigators will have identified probe candidates via screening of small molecule collections, using in vitro assays of biological activity developed to interrogate these collections, and be able to show that the structural features of these small molecules are related to their biological activity.
URL for PAR-09-251 -R21:
URL for PAR-09-259 -R41:
URL for PAR-09-260 -R43:

Small Business Innovation Research (SBIR) Program Contract Solicitation (PHS 2010-1) (NIH) (NOT-OD-09-137)
Contract proposal receipt date: November 9, 2009
See the announcement for research topics.

Centers for Medical Countermeasures Against Radiation (U19) (NIAID) (RFA-AI-09-036)
Letters of Intent Receipt Date: November 16, 2009
Application Receipt Date(s): December 15, 2009
The NIAID invites new or renewal applications from single institutions or consortia of institutions with multi-disciplinary investigator teams to participate in the Centers for Medical Countermeasures against Radiation (CMCR) program. The primary goal is to support development of new medical products that will assess, diagnose, mitigate and/or treat the short- and long-term consequences of radiation exposure after a radiological/nuclear terrorist event.

Clarification: NHLBI Does Not Accept R21 Applications Primarily Related to Cancer Research
Since there are areas of overlap, applicants are strongly encouraged to contact the NHLBI before submitting an application in response to PA-09-164.

Recovery Act of 2009: Opens for Registration (NOT-OD-09-138)
Prime grantee institutions that received NIH ARRA awards must be registered prior to submitting the quarterly recipient reports required under ARRA.URL:

Reminder: Investigators Should Update their eRA Commons Profiles to Include Degree and Residency Completion Dates(NOT-OD-09-134)
We ask that all New Investigators check their eRA Commons profile at and if necessary provide the requested degree date and/or the date of completion of medical residency. The dates entered will be used to determine the beginning and end date of the Early Stage Investigator period. New Investigator status is based on a search of NIH records for evidence of previous, substantial, competing NIH research grant support. Both the New Investigator and ESI status will be displayed on the eRA Commons website.

Notice of Deadline Extension for Program Announcement on Bioengineering Research Grants (Multiple Institutes, not including NCI) (NOT-EB-09-003)

Extended Expiration Date for Program Announcement on Exploratory/Developmental Bioengineering Research Grants (R21)(Multiple Institutes, not including NCI) (NOT-EB-09-004)

CIP Announcements

The Cancer Imaging Program’s DCIDE program for providing data to investigators for their IND filings is being absorbed by the NCI Experimental Therapeutics Program (NExT). On the web site, click on the NExT icon to start submission of a NExT application. The first round of submissions are due September 15, 2009, and quarterly after that starting November 15, 2009. Click on the instructions to see what you need to do to apply. The reviews are to be handled by outside Special Emphasis Panels empanelled for the purpose.

The Molecular Imaging and Contrast Agent Database (MICAD) program has been developed as a key component of the NIH Molecular Imaging Roadmap to provide freely accessible online scientific information on in vivo molecular imaging and contrast agents. To accelerate expansion of the database to include all published agents, the MICAD program has implemented a procedure for members of the imaging community to write and submit entries (chapters) as guest authors to the database. All members of the imaging community are encouraged to consider this guest author opportunities. For further information, please contact the MICAD staff at Individual guest authors will be provide with detailed instructions, style guidelines, and a chapter template. The name of the contributing author(s) will be acknowledged and included in the MICAD online publication.


World Molecular Imaging Congress
September 23 - 26, 2009, Montreal, Quebec Canada

RSNA 2010 Clinical Trials Methodology Workshop
January 9-15, 2010, Hyatt Regency, Scottsdale, Arizona
Apply on line by June 8, 2009.

The Cancer Imaging Program at NCI has created this e-mail distribution list to notify interested people about funding opportunities and other issues related to imaging research. Its primary purpose is to call your attention to important, relevant information on NIH Web pages, or in the NIH Guide. Occasionally it may be used to clarify areas of confusion, or disseminate answers to frequently asked questions.

If you wish to remain on the list, no action is necessary. If you wish to be added to the list, please contact Dr Barbara Croft by return e-mail ( Please include your complete mailing address, title, phone and fax numbers.

Cancer Imaging Program
Division of Cancer Treatment and Diagnosis, NCI
6130 Executive Boulevard - MSC-7412
Bethesda, MD 20892-7412
Tel: 301 496 9531
Fax: 301 480 3507